UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
Commission File Number 0-18160
------
NOTIFICATION OF LATE FILING
(Check One): /./ Form 10-K / / Form 11-K / / Form 20-F /X/ Form 10-Q
/ / Form N-SAR
For Period Ended: March 31, 2000
--------------------------------------------------------------
/ / Transition Report on Form 10-K / / Transition Report on Form 10-Q
/ / Transition Report on Form 20-F / / Transition Report on Form N-SAR
/ / Transition Report on Form 11-K
For the Transition Period Ended:
----------------------------------------------
Read attached instruction sheet before preparing form. Please print or
type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
- -------------------------------------------------------------------------------
PART I. REGISTRANT INFORMATION
Full name of registrant Omni Nutraceuticals, Inc.
-------------------------------------------------------
Former name if applicable N/A
- -------------------------------------------------------------------------------
Address of principal executive office (Street and number)
5310 Beethoven
- -------------------------------------------------------------------------------
City, State and Zip Code Los Angeles, CA 90066
------------------------------------------------------
PART II. RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check appropriate box.)
/X/ (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
/X/ (b) The subject annual report, semi-annual report, transition report on
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the 15th calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and
/ / (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III. NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 10-Q,
N-SAR or the transition report or portion thereof, could not be filed within the
prescribed time period. (Attach extra sheets if needed.)
Data and other information regarding certain material operations of the Company
- ------------------------------------------------------------------------------
as well as its financial statements required for the filing are not currently
- ------------------------------------------------------------------------------
available and could not be made available without unreasonable effort and
- --------------------------------------------------------------------------------
expense.
- ------------------------------------------------------------------------------
PART IV. OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
M. Richard Cutler (949) 719-1977
- -------------------------------------------------------------------------------
(Name) (Area code) (Telephone number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). /X/ Yes / / No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statement to be included in the subject report or portion thereof?
/X/ Yes / / No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
The registrant anticipates that it will incur a net loss of approximately
- --------------------------------------------------------------------------------
$9 million in the quarter ended March 31, 2000, verses a net loss of $0.2
- --------------------------------------------------------------------------------
million for the comparable quarter in 1999. This loss was primarily the result
- --------------------------------------------------------------------------------
of equity based settlement and financing costs; increased advertising and
- -------------------------------_------------------------------------------------
promotion expenses, high returns/allowances, and higher accounting fees.
- --------------------------------------------------------------------------------
Omni Nutraceuticals, Inc.
- -------------------------------------------------------------------------------
(Name of registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date May 11, 2000 By: /s/: Klee Irwin
------------------- -----------------------------------------------------
Name: Klee Irwin
Title: Chief Executive Officer
Instruction. The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of
the representative's authority to sign on behalf of the registrant shall be
filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal criminal
violations (see 18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b-25 (17 CFR 240, 12b-25) of the General
Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange
Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained in
or filed with the Form will be made a matter of the public record in the
Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed
with each national securities exchange on which any class of securities of
the registrant is registered.
4. Amendments to the notifications must also be filed on Form 12b-25 but need
not restate information that has been correctly furnished. The form shall
be clearly identified as an amended notification.
5. Electronic Filers. This form shall not be used by electronic filers unable
to timely file a report solely due to electronic difficulties. Filers
unable to submit a report within the time period prescribed due to
difficulties in electronic filing should comply with either Rule 201 or
Rule 202 of Regulation S-T ((0)232.201 or (0)232.202 of this chapter) or
apply for an adjustment in filing date pursuant to Rule 13(b) of
Regulation S-T ((0)232.13(b) of this chapter). [Added in Release No.
34-31905 (85,111), effective April 26, 1993, 58 FR 14628; and Release No.
34-35113 (85,475), effective January 30, 1995, 59 F.R. 67752.
